Fine, Amanda (NIH/OD) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP From:

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=61290B74AA9A44358954C45439FFDEB6-FINEAB]

Sent: 4/16/2019 9:12:01 PM

To: Rohrbaugh, Mark (NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=591ab6b2424b4b8997082718cbb29fab-rohrbaum]; Wojtowicz, Emma

(NIH/OD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=45c6610aca6e44a08d497630425e5ecd-wojtowiczem]

Subject: RE: Background info on CAR T license to Gilead

Attachments: Interview request: exclusive license for a CAR-T therapy

Hi Mark-

Sorry for the delay--are you looking for the attached?

Thanks, Amanda

----Original Message----

From: Rohrbaugh, Mark (NIH/OD) [E] <rohrbaum@od.nih.gov>

Sent: Tuesday, April 16, 2019 12:06 PM

To: Fine, Amanda (NIH/OD) [E] <amanda.fine@nih.gov>; Wojtowicz, Emma (NIH/OD) [E]

<emma.wojtowicz@nih.gov>

Subject: FW: Background info on CAR T license to Gilead

Do you have the sheet we prepared for reporters on the CAR-T technology last year?

Thanks,

----Original Message----

From: Joe Allen <jallen@allen-assoc.com>

Sent: Tuesday, April 16, 2019 11:01 AM To: Rohrbaugh, Mark (NIH/OD) [E] <rohrbaum@od.nih.gov> Subject: Background info on CAR T license to Gilead

Thanks

Joseph P. Allen President Allen and Associates 60704 Rt. 26, South Bethesda, OH 43719 (W) 740-484-1814 (c) b6 www.allen-assoc.com